<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75401">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718444</url>
  </required_header>
  <id_info>
    <org_study_id>12-006213</org_study_id>
    <nct_id>NCT01718444</nct_id>
  </id_info>
  <brief_title>Clomiphene Citrate Fast-Track Protocol for Fertility Treatment in Women With PCOS</brief_title>
  <official_title>Optimizing Fertility Treatment in Women With Polycystic Ovary Syndrome (PCOS) Using the Clomiphene Citrate Fast-Track Protocol: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with polycystic ovary syndrome (PCOS) have traditionally been treated for infertility
      by using progestin for a withdrawal bleed (aka endometrial shedding) before clomiphene
      citrate (CC) is administered to induce ovulation.

      Recent evidence suggests that this approach (the traditional CC protocol) may be associated
      with decreased pregnancy and live birth rates, compared to the &quot;fast track&quot; CC protocol (in
      which no progestin is used).

      The investigators are performing the first randomized controlled trial to find out if
      skipping the use of progestin (fast track CC protocol) during fertility therapy of
      anovulatory PCOS women leads to improved pregnancy and live birth rates compared to the
      traditional CC protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical pregnancy confirmed by pelvic ultrasound</measure>
    <time_frame>Within 3 weeks of a positive pregnancy test</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first ovulation</measure>
    <time_frame>Within 3 months of start of CC</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical pregnancy</measure>
    <time_frame>Within 6 months of start of CC</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth</measure>
    <time_frame>Delivery after 24 weeks of pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Clomiphene Citrate Fast-Track Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this group will be managed using the Clomiphene Citrate (Clomid) fast-track protocol and will receive Clomid without using Progestin throughout their treatment course.
Clomid 50 mg oral for 5 days (Day 3-7)
If no ovulation, Clomid 100 mg for 5 days (Day 12-16)
If no ovulation, Clomid 150 mg for 5 days (Day 21-25)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional Clomiphene Citrate Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women randomized to this group will receive Clomiphene Citrate (Clomid) using a traditional incremental-dose protocol, with Progestin given to induce a withdrawal bleed before starting any doses of Clomid.
Progestin 10 mg oral for 10 days to induce a withdrawal bleed
Clomid 50 mg oral for 5 days (Day 3-7)
If no ovulation, Progestin 10 mg for 10 days to induce withdrawal bleed (Day 21-30) and Clomid 100 mg for 5 days (Day 36-40)
If no ovulation, Progestin 10 mg for 10 days to induce withdrawal bleed (Day 54-63) and Clomid 150 mg for 5 days (Day 69-73)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progestin</intervention_name>
    <arm_group_label>Traditional Clomiphene Citrate Protocol</arm_group_label>
    <other_name>Provera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <arm_group_label>Clomiphene Citrate Fast-Track Protocol</arm_group_label>
    <arm_group_label>Traditional Clomiphene Citrate Protocol</arm_group_label>
    <other_name>Clomid</other_name>
    <other_name>Clomiphene citrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Women ages 18 - 35, desiring pregnancy

          -  Established diagnosis of PCOS confirmed by the Rotterdam criteria

          -  Oligo or anovulatory, with menstrual cycles &gt; 35 days apart or less than 9 menstrual
             cycles per year

          -  Normal vaginal ultrasound with endometrial stripe &lt; 12mm

          -  Normal thyroid stimulating hormone (TSH) within past one year

          -  Normal prolactin (PRL) within past one year

          -  For women with previous successful Clomid treatment, a washout period of at least 6
             months is required

          -  Negative beta hcg within past one month

          -  Negative progesterone within past one month

        Exclusion

          -  BMI &gt; 40

          -  Regular menstrual cycles occurring less than 35 days apart

          -  Evidence of other infertility factors such as endometriosis, tubal factor or male
             infertility

          -  Prior unsuccessful Clomid ovulation cycles

          -  Abnormal vaginal ultrasound findings such as endometrial polyps, submucous myomas,
             synechiae

          -  Uterine anomaly such as unicornuate or bicornuate uterus

          -  Presence of hydrosalpinx

          -  Evidence of active endocrinopathy

          -  Abnormal TSH

          -  Abnormal PRL

          -  Partner with abnormal semen analysis (count &lt; 15 million sperm /ml)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jani Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen A Lemens, BSN</last_name>
    <phone>507-293-1487</phone>
    <email>lemens.maureen@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Albert Asante, MD, MPH</last_name>
    <phone>507-284-4520</phone>
    <email>asante.albert@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen A Lemens, RN</last_name>
      <phone>507-293-1487</phone>
      <email>lemens.maureen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jani R Jensen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Asante, M.B.B.Ch.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>October 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jani Jensen</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics-Gynecology, Consultant in Reproductive Endocrinology and Infertility</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Infertility</keyword>
  <keyword>Anovulation</keyword>
  <keyword>Clomiphene citrate</keyword>
  <keyword>Clomid</keyword>
  <keyword>Progestin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
